Taro Pharmaceuticals to Acquire Antibe Therapeutics

Taro Pharmaceuticals Inc., a subsidiary of Sun Pharmaceutical Industries Ltd., has reached an agreement to acquire hundred percent of Antibe Therapeutics Inc., a Canadian biotechnology firm.

About Antibe Therapeutics

Antibe Therapeutics, based in Ontario, is a clinical-stage biotechnology company founded in 2009.

Taro Pharmaceuticals focuses on developing innovative drugs aimed at reducing pain and inflammation.

However, Antibe has not reported any revenue from operations over the past three years, as confirmed by Sun Pharma in a statement to the Bombay Stock Exchange.

Transaction Details and Conditions

The acquisition is subject to a ‘reverse vesting order’ and requires approval from the Ontario Superior Court of Justice (Commercial List). Sun Pharma anticipates that the transaction will be finalized before March 7, 2025.

Funding and Disclosure Information

As reported by thehindubusinessline.com, the Ontario court is overseeing the divestment of Antibe. The court-appointed receiver has stated that the acquisition consideration will not be disclosed. This will occur only after the deal is closed.

Related Posts

  • Pharma
  • February 17, 2025
  • 73 views
GSK Pharma shares gain 20% following strong Q3FY25 results

GSK Pharma shares gained by 20 percent on Monday, February 17, as brokerages like ICICI Securities and Motilal Oswal continue to maintain positive rating of the stock. GlaxoSmithKline Pharmaceuticals Ltd…

  • Pharma
  • February 17, 2025
  • 68 views
Glenmark Pharma shares rise 4% on Q3 results, FY26 guidance

Shares of Glenmark Pharmaceuticals Ltd rose 4% on February 17 after the firm gave a strong guidance for FY26 and it returned to black in the December quarter. The drugmaker…

Leave a Reply

Your email address will not be published. Required fields are marked *

You Missed

Wow! What a Change of Heart in Practitioners of Allopathy!

Wow! What a Change of Heart in Practitioners of Allopathy!

GSK Pharma shares gain 20% following strong Q3FY25 results

GSK Pharma shares gain 20% following strong Q3FY25 results

Glenmark Pharma shares rise 4% on Q3 results, FY26 guidance

Glenmark Pharma shares rise 4% on Q3 results, FY26 guidance

US Tariffs on pharma: What are the potential impact on Indian drugmakers

US Tariffs on pharma: What are the potential impact on Indian drugmakers

Twin Health bats a1000 before enters Digital Health NY 100

Twin Health bats a1000 before enters Digital Health NY 100

US tariff jitters rock pharma stocks; Sun Pharma, Lupin, Dr Reddy’s slump 2-4%

US tariff jitters rock pharma stocks; Sun Pharma, Lupin, Dr Reddy’s slump 2-4%